Skip to main content
Erschienen in: International Journal of Hematology 3/2009

01.04.2009 | Case Report

Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution

verfasst von: Yosuke Matsumoto, Tomohiko Taki, Yoshiko Fujimoto, Kyoko Taniguchi, Daisuke Shimizu, Kazuho Shimura, Hitoji Uchiyama, Junya Kuroda, Kenichi Nomura, Tohru Inaba, Chihiro Shimazaki, Shigeo Horiike, Masafumi Taniwaki

Erschienen in: International Journal of Hematology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Biphenotypic acute leukemia co-expressing T-lymphoid and myeloid markers is rare, accounting for less than 1% of acute leukemias. However, several clinical characteristics including male predominance, frequent lymphadenopathy and unfavorable outcome have been identified. Recurrence of monosomies 7p and/or 12p in T/myeloid biphenotypic acute leukemia has been reported. We treated a patient with T/myeloid biphenotypic acute leukemia showing clonal chromosomal and genetic abnormalities including dic(7;12)(p11;p11) and Fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication. Cytogenetic analysis of both bone marrow and lymph node cells disclosed that the patient’s lymph node leukemia cells had chromosomal abnormalities in addition to dic(7;12). Our findings suggest that the leukemia cells of systemic lymphadenopathy had evolved as secondary cells from marrow leukemia cells. The patient was successfully treated with induction chemotherapy for acute myeloid leukemia followed by allogeneic bone marrow transplantation.
Literatur
1.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haemapoietic and lymphoid tissues. Lyon: IARC press; 2001. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haemapoietic and lymphoid tissues. Lyon: IARC press; 2001.
2.
Zurück zum Zitat Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the immunological characterization of leukemias (EGIL). Leukemia. 1995;9:1783–6.PubMed Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the immunological characterization of leukemias (EGIL). Leukemia. 1995;9:1783–6.PubMed
3.
Zurück zum Zitat Buccheri V, Matutes E, Dyer MJ, Catovsky D. Lineage commitment in biphenotypic acute leukemia. Leukemia. 1993;7:919–27.PubMed Buccheri V, Matutes E, Dyer MJ, Catovsky D. Lineage commitment in biphenotypic acute leukemia. Leukemia. 1993;7:919–27.PubMed
4.
Zurück zum Zitat Carbonell F, Swansbury J, Min T, et al. Cytogenetic findings in acute biphenotypic leukaemia. Leukemia. 1996;10:1283–7.PubMed Carbonell F, Swansbury J, Min T, et al. Cytogenetic findings in acute biphenotypic leukaemia. Leukemia. 1996;10:1283–7.PubMed
5.
Zurück zum Zitat Matutes E, Morilla R, Farahat N, et al. Definition of acute biphenotypic leukemia. Haematologica. 1997;82:64–6.PubMed Matutes E, Morilla R, Farahat N, et al. Definition of acute biphenotypic leukemia. Haematologica. 1997;82:64–6.PubMed
7.
Zurück zum Zitat Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMed Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMed
9.
10.
Zurück zum Zitat Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911–8.PubMed Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911–8.PubMed
12.
Zurück zum Zitat Killick S, Matutes E, Powles RL, et al. Outcome of biphenotypic acute leukemia. Haematologica. 1999;84:699–706.PubMed Killick S, Matutes E, Powles RL, et al. Outcome of biphenotypic acute leukemia. Haematologica. 1999;84:699–706.PubMed
14.
Zurück zum Zitat Owaidah TM, Al Beihany A, Iqbal MA, Elkum N, Roberts GT. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia. 2006;20:620–6. doi:10.1038/sj.leu.2404128.CrossRefPubMed Owaidah TM, Al Beihany A, Iqbal MA, Elkum N, Roberts GT. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia. 2006;20:620–6. doi:10.​1038/​sj.​leu.​2404128.CrossRefPubMed
15.
Zurück zum Zitat Nakao M, Janssen JW, Erz D, Seriu T, Bartram CR. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia. 2000;14:522–4. doi:10.1038/sj.leu.2401695.CrossRefPubMed Nakao M, Janssen JW, Erz D, Seriu T, Bartram CR. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease. Leukemia. 2000;14:522–4. doi:10.​1038/​sj.​leu.​2401695.CrossRefPubMed
17.
Zurück zum Zitat Xu F, Taki T, Yang HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155–62. doi:10.1111/j.1365-2141.1999.01284.x.CrossRefPubMed Xu F, Taki T, Yang HW, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155–62. doi:10.​1111/​j.​1365-2141.​1999.​01284.​x.CrossRefPubMed
20.
Zurück zum Zitat Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1,135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658–65. doi:10.1182/blood-2005-03-1323.CrossRefPubMed Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1,135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658–65. doi:10.​1182/​blood-2005-03-1323.CrossRefPubMed
22.
Zurück zum Zitat Ponziani V, Gianfaldoni G, Mannelli F, et al. The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia. 2006;20:2074–6. doi:10.1038/sj.leu.2404368.CrossRefPubMed Ponziani V, Gianfaldoni G, Mannelli F, et al. The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia. 2006;20:2074–6. doi:10.​1038/​sj.​leu.​2404368.CrossRefPubMed
Metadaten
Titel
Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution
verfasst von
Yosuke Matsumoto
Tomohiko Taki
Yoshiko Fujimoto
Kyoko Taniguchi
Daisuke Shimizu
Kazuho Shimura
Hitoji Uchiyama
Junya Kuroda
Kenichi Nomura
Tohru Inaba
Chihiro Shimazaki
Shigeo Horiike
Masafumi Taniwaki
Publikationsdatum
01.04.2009
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2009
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0268-7

Weitere Artikel der Ausgabe 3/2009

International Journal of Hematology 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.